AVISE Lupus Test Improves Disease Diagnosis and Helps Guide Treatment Decisions
Newly published research further demonstrates the effectiveness of the lupus diagnostic test known as the AVISE Lupus test. Physician confidence in diagnosing lupus increased with increasing AVISE test scores, and physicians felt more confident ruling in the possibility of lupus based on positive AVISE test results compared to the commonly used anti-dsDNA lab test.
Additionally, the AVISE test also helped increase physicians’ confidence in ruling out lupus compared to the anti-dsDNA test and helped guide their treatment decisions. With increasing AVISE scores, physicians were more likely to begin treating patients such as with hydroxychloroquine (Plaquenil), an important and commonly prescribed medication in the treatment of lupus.
Lupus is a difficult disease to identify, and because of this it often takes many years before people with lupus receive a diagnosis. To help improve diagnostic lab tests for lupus, the Lupus Foundation of America (LFA) partnered with the life science company Exagen to support early research on the development of the AVISE test. To date, multiple studies have shown that this advanced test can help reduce time to early and accurate lupus diagnosis, allowing people to get the treatment they need as soon as possible.